HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ulipristal Acetate

HCID 130904
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
126784-99-4
Standard SMILES
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
InChIKey
OOLLAFOLCSJHRE-ZHAKMVSLSA-N
Molecular formula
C30H37NO4
Average molar mass
475.6 g/mol
Monoisotopic mass
475.27225866

Overview

Ulipristal acetate is a 20-oxo steroid obtained by acetylation of the 17-hydroxy group of (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-ol (ulipristal). A selective progesterone receptor modulator, which is employed as an emergency contraceptive. It has a role as a contraceptive drug, a progestin and a progesterone receptor modulator. It is a 20-oxo steroid, an acetate ester, a steroid ester, a 3-oxo-Delta(4) steroid and a tertiary amino compound. It is functionally related to an estradiol.

Names & identifiers

Preferred name
Ulipristal Acetate
IUPAC
[(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
English name
Ulipristal Acetate
Molecular formula
C30H37NO4
Molecular weight
475.62

Names & synonyms

Ulipristal acetate126784-99-4EllaEllaOneCDB-2914VA2914YF7V70N02BRTI-3021-012PGL-4001(11beta)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dioneVA-291417-Acetoxy-11-(4-N,N-dimethylaminophenyl)pregna-4,9-diene-3,20-dione
Show more names
Ulipristal17α-Acetoxy-11β-(4-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dioneUliprisnil AcetateCDB2914VA 2914RU 44675CBD 2914HRP 2000
CHEBI:71025DTXSID30155294(11beta)-17-(Acetyloxy)-11-(4-(dimethylamino)phenyl)-19-norpregna-4,9-diene-3,20-dioneEsmya17beta-acetyl-11beta-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17alpha-yl acetate[(8S,11R,13S,14S,17R)-17-acetyl-11-(4-dimethylaminophenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate17beta-acetyl-11beta-(4-(dimethylamino)phenyl)-3-oxoestra-4,9-dien-17alpha-yl acetate((8S,11R,13S,14S,17R)-17-acetyl-11-(4-dimethylaminophenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta(a)phenanthren-17-yl) acetate

Properties

Computed structural properties

XLogP
3.5
Topological polar surface area
63.7 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
5
Rotatable bonds
5
Heavy atoms
35
Formal charge
0
Complexity
984

Experimental & physicochemical properties

Human Drugs · 3 items

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Endocrine DisruptorsPotential endocrine disrupting compound

Physicochemical properties

Melting point
183 · 183-185 ºC
Boiling point
640.1 · 640.1±55.0 °C(Predicted)
Density
1.19 · 1.19
storage temp.
-20 °C · -20°C
solubility
Chloroform, Ethyl Acetate, Methanol
pka
5.49 · 5.49±0.24(Predicted)
form
powder
color
white to beige
optical activity
165 to · [α]/D +165 to +185°, c = 1 in dichloromethane
InChIKey
OOLLAFOLCSJHRE-JUBWNBEVNA-N

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (75%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 8 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (75%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ulipristal acetate

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Safety data

wgk
WGK 3
hs_code
2937.29.9095
Signal word
Warning
Symbol(GHS)
GHS08
Storage Class
11 - Combustible Solids
Hazard statements
H361fd
Hazard Classifications
Repr. 2
Precautionary statements
P280

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 2 items

ULIPRISTAL ACETATE

Selective Progesterone Receptor Modulators [MoA]; Progesterone Agonist/Antagonist [EPC]

MeSH Pharmacological Classification · 2 items

Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.

Contraceptive agents that act on the ENDOCRINE SYSTEM.

Applications · 5 items

DescriptionUlipristal acetate (UPA) is a selective progesterone receptor modulator. Attributing to its higher efficacy and a similar rate of side effects compared to levonorgestrel emergency contraception, it is now recommended as first line treatment for emergency contraception. Emergency contraception is defined as the use of drug or device after unprotected or under-protected intercourse to prevent an unwanted pregnancy. Ulipristal acetate can be used up to 5 days (120 h) after unprotected sexual intercourse. As progesterone promotes the growth of uterine fibroids, the blocking characteristic of ulipristal acetate can thereby be used to reduce the size of uterine fibroids. Ulipristal acetate has also shown efficacy with a significant reduction in uterine bleeding caused by uterine fibroids. The treatment of fibroids by ulipristal acetate should begin in the first week of a menstrual period. Drugs or herbal products that induce enzymes, including CYP3A4, such as carbamazepine, phenytoin, rifampin, St. John's Wort, etc., may decrease the plasma concentrations of ulipristal acetate, and may decrease its effectiveness while CYP3A4 inhibitors such as itraconazole, ketoconazole, etc., may increase plasma concentrations of ulipristal acetate. The half-life after oral intake is 32 h; it binds to plasma proteins for 97–99%, and it is metabolized by the citochrome P450.

DescriptionUlipristal acetate is a synthetic steroid derived from 19-nor-progesterone that exerts potent progesterone receptor (PR) antagonist activity at the transcriptional level. It is an orally administered drug indicated for emergency contraception (i.e., postcoital contraception) up to 120 h following unprotected intercourse. Ulipristal acetate is the second oral progestogen marketed for this indication behind levonorgestrel. As PR antagonists, both drugs are believed to act via delay of ovulation and inhibition of follicular development. Levonorgestrel 1.5 mg is approved for contraception up to 72 h following unprotected intercourse and is widely accessible via prescription, and directly from clinics and community pharmacies. Prior to ulipristal acetate, the only approved postcoital contraceptive option between 72 and 120 h was the insertion of an intrauterine device (IUD). The recommended dose of ulipristal acetate is one 30-mg tablet taken as soon as possible and no more than 120 h following intercourse. The vast majority of PR antagonists belonging to the mifepristone (RU486) family also bind to the glucocorticoid receptor (GR) with high affinity and thereby exert antiglucocorticoid activity. The most common adverse effects with ulipristal acetate were headache, dysmenorrhea, nausea, abdominal pain, dizziness, fatigue, and upper abdominal pain.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
126784-99-4
PubChem CID
130904
DTXSID
DTXSID30155294
ChEMBL
CHEMBL260538
ChEBI
CHEBI:71025
UNII
YF7V70N02B
EC Number
682-170-1
Nikkaji
J533.262A
SMILES
C1CC2=C3[C@@H](c4ccc(N(C)C)cc4)C[C@@]4([C@@](OC(=O)C)(C(=O)C)CC[C@H]4[C@@H]3CCC2=CC1=O)C |&1:4,15,16,26,27,r|
FDA UNII
7 V70N02B · YF7V70N02B
NCI Drug Dictionary
ulipristal acetate
ATC code
3 AD02,G03XB02 · G03AD02,G03XB02
Comptox DTXSID
30155294 · DTXSID30155294
UNSPSC Code
51111800 · 51111800
NACRES
77 · NA.77
Symbol(GHS)
8 · GHS08
Signal word
Warning
Hazard statements
361 fd · H361fd
Precautionary statements
280 · P280
WGK Germany
3 · WGK 3
HS Code
2937.29 · 2937.29.9095
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 · Repr. 2

UsesΑ selective labelled progesterone receptor modulator

UsesUlipristal acetate is a selective progesterone receptor modulator

UsesLabelled Ulipristal

Additional notes · 1 item

DefinitionChEBI: A 20-oxo steroid obtained by acetylation of the 17-hydroxy group of (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-ol (ulipristal). A selective progesterone receptor modulator, which is empl yed as an emergency contraceptive.